Search results
Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting
WFRV 5 Green Bay· 2 days agoNanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for retinal degenerative diseases, today announced that its Multi-Characteristic Opsin (MCO ...
Retinal hemorrhage: Causes, risk factors, and symptoms
Medical News Today· 4 days agoWhat is a retinal hemorrhage? Read on to learn more about bleeding in the eye, including different...
Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema
Digital Journal· 4 days agoEmmecell has a broad intellectual property (IP) portfolio and is focusing its initial efforts on ophthalmic indications, including corneal edema and macular degeneration ...
The Real Reason Behind The ‘Epidemic’ of Nearsightedness — And How To Fix It
Inverse· 10 hours agoMyopia, or the need for corrected vision to focus or see objects at a distance, has become a lot...
Kodiak Sciences Inc. (NASDAQ:KOD) Given Average Rating of “Reduce” by Analysts
ETF DAILY NEWS· 3 days agoKodiak Sciences Inc. (NASDAQ:KOD – Get Free Report) has been assigned an average rating of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat reports. Three ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 5 days agoCognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced ...
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024
WJTV Jackson· 1 day agoJohnson & Johnson today announced that eight company-sponsored presentations will be featured during the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting taking ...
Research Analysts Set Expectations for Adverum Biotechnologies, Inc.’s Q1 2024 Earnings...
ETF DAILY NEWS· 19 hours agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Adverum Biotechnologies in a note ...
Letters: Fluctuating costs of prescription drugs demand change
Chicago Tribune· 5 days agoUnjust and rapid prescription drug costs continue to put significant financial strain on Illinois...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoFirst quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first
